[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-therapy-related-cardiac-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-therapy-related-cardiac-dysfunction":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,84,112,151,184],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100640884","structured-cardio-oncology-rehabilitation-for-cardiovascular-outcomes-in-cancer-survivors-100640884",false,"NCT07622394","Structured Cardio-Oncology Rehabilitation for Cardiovascular Outcomes in Cancer Survivors","A Multicenter, Prospective, Parallel-Group, Superiority Randomized Controlled Trial of Structured Cardio-Oncology Rehabilitation for Improving Cardiovascular Outcomes in Patients With Cancer Therapy-Related Cardiac Dysfunction or High Cardiovascular Risk","CORE-CTRCD","Inclusion Criteria:\n\n* Age 18 years or older, regardless of sex.\n* Histologically or cytologically confirmed solid tumor or hematologic malignancy.\n* Completed curative anti-cancer therapy, or receiving stable adjuvant, maintenance, or palliative anti-cancer therapy.\n* Meets at least one criterion for cancer therapy-related cardiac dysfunction (CTRCD) or high cardiovascular risk, including reduced LVEF after anti-cancer therapy, high-dose anthracycline exposure, chest radiotherapy with cardiovascular risk factors, heart failure after anti-cancer therapy, or elevated cardiac injury\u002Fheart failure biomarkers.\n* Estimated life expectancy of at least 24 months as assessed by the treating oncologist.\n* Able to complete baseline cardiopulmonary exercise testing and has no absolute contraindication to exercise training.\n* Able and willing to provide written informed consent and comply with study intervention and follow-up.\n\nExclusion Criteria:\n\n* Active progressive malignancy requiring urgent anti-cancer therapy, or estimated life expectancy less than 24 months.\n* Severe structural heart disease, including severe valvular disease, congenital heart disease, end-stage heart failure, or waiting for heart transplantation or left ventricular assist device implantation.\n* Absolute contraindications to exercise training, including uncontrolled malignant arrhythmia, acute myocarditis or pericarditis, acute coronary syndrome within 2 weeks, severe anemia, severe thrombocytopenia or neutropenia, uncontrolled hypertension, active infection, or severe musculoskeletal disease preventing exercise training.\n* Participation in a structured cardiac rehabilitation program within the previous 12 months, or regular moderate-to-vigorous aerobic or resistance training for at least 3 months before enrollment.\n* Implanted ICD or CRT, except pacemakers with exercise mode.\n* Severe psychiatric disease or cognitive impairment preventing participation.\n* Concurrent participation in another interventional clinical trial, or planned participation in another interventional clinical trial during the study period.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.","ALL","18 Months",{"count":20,"type":21},800,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cancer therapy-related cardiac dysfunction (CTRCD) has become a major cause of morbidity and mortality among cancer survivors. Although cardiac rehabilitation is recommended for cardiovascular disease prevention and management, high-quality randomized controlled evidence regarding its efficacy in cardio-oncology populations remains limited.\n\nThis multicenter, prospective, parallel-group, superiority randomized controlled trial aims to evaluate whether a structured cardio-oncology rehabilitation (CORE) program combined with usual care can improve cardiovascular outcomes in patients with CTRCD or cancer survivors at high cardiovascular risk, compared with usual care alone.\n\nA total of 800 participants will be randomized in a 1:1 ratio to receive either structured cardio-oncology rehabilitation plus usual care or usual care alone. The intervention includes individualized exercise training, nutritional management, psychosocial support, cardiovascular risk-factor optimization, and patient education. Participants will be followed for 12 months.\n\nThe primary endpoint is time to first major adverse cardiovascular event (MACE) within 12 months. Secondary endpoints include changes in cardiorespiratory fitness, cardiac function, biomarkers, quality of life, physical function, psychological status, safety outcomes, and health economic outcomes.",[27,28,29,30,31],"Cancer Therapy-Related Cardiac Dysfunction","Cardio-oncology","Cancer Survivorship","Cardiovascular Risk","Heart Failure",[33,34,35,36,37,38,39],"Structured Cardio-Oncology Rehabilitation","Cardiac Rehabilitation","Cancer Survivors","Major Adverse Cardiovascular Events","Exercise Training","Cardiorespiratory Fitness","CTRCD","NOT_YET_RECRUITING","2026-06-02",{"date":43,"type":44},"2026-06-03","ACTUAL",{"date":46,"type":21},"2026-09-01",{"date":48,"type":21},"2029-09-30",{"name":50,"class":51},"Xinjiang Medical University","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":82,"locationsCount":52},"100638118","cardiac-side-effects-of-systemic-therapy-in-early-stage-breast-cancer-100638118","NCT07588425","Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer","Prospective and Molecular Biomarker-Based Evaluation of Cardiac Side Effects in Patients With Early-Stage Breast Cancer Receiving Systemic Therapy: A Single-Center Observational Cohort Study","C-BREAST-01","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of breast cancer\n* Stage I, II, or III disease\n* Planned neoadjuvant or adjuvant chemotherapy and\u002For HER2-targeted systemic therapy\n* Baseline transthoracic echocardiographic left ventricular ejection fraction (LVEF) ≥ 50%\n* Age ≥ 18 years\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Metastatic (Stage IV) breast cancer\n* Pre-existing heart failure or clinically significant cardiac disease\n* Prior exposure to chemotherapy or other cardiotoxic systemic therapy\n* Concurrent active malignancy other than breast cancer\n* Inability or unwillingness to comply with the planned follow-up and assessment schedule","FEMALE","18 Years",{"count":64,"type":21},100,"OBSERVATIONAL","The goal of this observational study is to evaluate cardiac side effects in women with early-stage breast cancer who receive systemic chemotherapy and\u002For anti-HER2 therapy as part of their standard cancer care.\n\nThe main questions it aims to answer are:\n\nCan changes in Global Longitudinal Strain (GLS) on echocardiography detect early cardiac dysfunction before a drop in left ventricular ejection fraction (LVEF) becomes apparent? Are changes in circulating microRNA levels in the blood associated with early cardiac dysfunction during cancer treatment? Does cardiac dysfunction occur more frequently with anthracycline-containing chemotherapy compared to anthracycline-free regimens?\n\nParticipants already receiving standard chemotherapy and\u002For anti-HER2 therapy as part of their routine cancer care will undergo echocardiography (LVEF and GLS), provide blood samples for microRNA analysis, and complete quality of life questionnaires at four time points: before treatment (baseline), and at 3, 6, and 12 months after starting treatment.",[68,69,27],"Breast Cancer (Early Breast Cancer)","Cardiotoxicity",[71,72,73,69,74,75,28],"Early-stage breast cancer","Anthracyclines","Anti-HER2 therapy","GLS","microRNA","2026-05-10",{"date":78,"type":44},"2026-05-14",{"date":76,"type":21},{"date":81,"type":21},"2028-03-30",{"name":83,"class":51},"Fatih GURLER",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":61,"minAge":62,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100583869","cardiac-rehabilitation-program-on-the-prevention-of-cardiotoxicity-in-breast-cancer-patients-undergoing-treatment-with-anthracyclines-andor-trastuzumab-100583869","NCT06881940","Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and\u002For Trastuzumab","Rationale and Design of a Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and\u002For Trastuzumab: A Randomized, Active Control Group, Open-Label Trial","CARPTOX-BC","Inclusion Criteria:\n\n* Women aged between 18 and 70 years will be considered eligible.\n* Active residents of any municipality within Mexico City and the surrounding metropolitan area will qualify, conditioned that their maximum travel time from their residence to our recruitment center does not exceed three hours using private or public transportation. This criterion is established to ensure adherence to the protocol and availability for participation in the required interventions and assessments throughout the study.\n* Patients diagnosed with early-stage or locally advanced breast cancer (stages I, II, or III, according to the TNM classification-Tumor, Node, Metastasis) who will undergo treatment with anthracyclines and\u002For adjuvant\u002Fneoadjuvant anti-HER2 therapy will be included. Participants must be scheduled to receive pharmacological treatment, ensuring that the study focuses on a population undergoing specific therapies for breast cancer management.\n* Candidates must have the capacity, availability, and willingness to participate in an aerobic and resistance exercise program. Participants are required to possess both the physical ability and the willingness to actively engage in a structured exercise program, which includes aerobic and resistance activities essential to the study's objectives.\n* Patients will provide informed written consent to participate in the study. To uphold ethical research principles and ensure the protection of participants' rights, all patients must voluntarily give their informed consent after receiving comprehensive information regarding the study's objectives, procedures, benefits, and potential risks.\n\nExclusion Criteria:\n\n* Metastatic disease: Individuals with medical or imaging evidence of metastasis to any peripheral organ.\n* Cardiovascular disease: Patients with a self-reported history of cardiovascular conditions, such as heart failure or uncontrolled hypertension, that may limit their ability to safely engage in physical activity. Additionally, those with peripheral arterial disease or valvular heart disease will not be eligible.\n* Ischemic heart disease: Patients with a history of ischemic heart disease.\n* Neurological disorders: Individuals with self-reported neurological diseases that significantly impair coordination, balance, or motor control, such as advanced Parkinson's disease, late-stage multiple sclerosis, or paralysis, making physical activity unsafe.\n* Musculoskeletal conditions: Patients with self-reported musculoskeletal injuries or disorders that hinder physical activity, including fractures within the last five years, moderate to severe sprains, tendinitis, or severe arthritis.\n* Uncontrolled systemic comorbidities: Individuals with decompensated systemic conditions, including heart failure, chronic kidney disease, or poorly controlled diabetes, will be excluded.\n* Severe respiratory diseases: Patients with severe respiratory conditions that prevent physical exercise participation.\n* Physical limitations: Individuals with mobility impairments or conditions requiring constant assistance for basic physical activities, such as those using assistive devices (e.g., wheelchairs, walkers) or with limb amputations, will not be eligible for participation.\n* Severe psychiatric disorders: Patients with uncontrolled psychiatric conditions, including schizophrenia, severe bipolar disorder, or major depressive disorder, that may interfere with their ability to actively participate in a supervised exercise program.\n\nElimination Criteria:\n\n* Voluntary withdrawal from the protocol.\n* Development of severe cardiotoxicity requiring pharmacological treatment.\n* Adverse reactions to chemotherapeutic agents.\n* Disease progression according to the TNM classification during treatment.\n* Failure to complete at least 80% of the prescribed adjuvant or neoadjuvant oncological treatment.\n* Occurrence of adverse events during the study, such as falls or injuries.\n* Death during the study period.\n* Any accident related to the exercise protocol, including falls, sprains, or fractures.","70 Years",{"count":94,"type":21},284,[24],"This study aims to evaluate the effectiveness of a cardiac rehabilitation protocol, incorporating aerobic and resistance exercise, in reducing the incidence of cardiotoxicity in breast cancer patients receiving treatment with anthracyclines and\u002For trastuzumab through a randomized, active control group, open-label clinical trial.",[27],[99,100,69,101,72],"Rehabilitation","Breast Neoplasms","Trastuzumab","2025-03-14",{"date":104,"type":44},"2025-03-18",{"date":106,"type":21},"2025-04-01",{"date":108,"type":21},"2029-12-01",{"name":110,"class":51},"Instituto Nacional de Cardiologia Ignacio Chavez",2,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":123,"conditions":124,"keywords":135,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100474986","phase-4-sacubitrilvalsartan-in-primary-prevention-of-the-cardiotoxicity-of-systematic-breast-cancer-treatment-mainstream-100474986","NCT05465031","Sacubitril\u002FValsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)","Sacubitril\u002FValsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent","Inclusion Criteria:\n\n* Written informed consent\n* Female gender, aged 18 years and over\n* Patients with histologically confirmed breast cancer and complete assessment of tumor phenotype (Estrogen receptor - ER, Progesterone receptor - PR, Human epidermal growth factor receptor 2 - HER2, Kiel - Ki67)\n* Ability to take oral medication and willingness to adhere to the planned regimen\n* Tumor grade IA-IIIC or oligometastatic grade IV\n* Radical treatment plan including surgery\n* Plan of use of systemic treatment (preoperative, postoperative or combined) with anthracyclines and\u002For anti-HER2 drugs\n* Eastern Cooperative Oncology Group (ECOG) 0-2 general status\n* LVEF ≥ 50% as assessed by echocardiography\n* Sinus rhythm\n\nExclusion Criteria:\n\n* Prior anthracycline-based chemotherapy and\u002For thoracic radiotherapy (prior to diagnosis of the cancer being the present cause of therapy)\n* Clinically relevant HF (NYHA II-IV)\n* Myocardial infarction (MI) within the last \\\u003C 3 months\n* Symptomatic hypotension or systolic blood pressure (SBP) \\\u003C 90 mmHg\n* Significant valvular disease, symptomatic coronary artery disease (CCS\\>2), significant atrioventricular (AV) block, symptomatic sinus node dysfunction\n* Expected survival \\\u003C12 months\n* Glomerular filtration rate (GFR) \\\u003C30 ml\u002Fmin\u002F1.73 m2 (screening visit)\n* K+\\>5.5mmol\u002FL (screening visit)\n* Contraindications to angiotensin converting enzyme inhibitor (ACE-I)\u002Fangiotensin II receptor blocker (ARB) or LCZ696 if not listed among criteria\n* Active untreated liver disease\n* Pregnancy\n* Conditions\u002Fcircumstances that may lead to non-compliance with medical staff recommendations (e.g. active drug\u002Falcohol dependence, poorly controlled mental illness)",{"count":120,"type":21},600,[122],"PHASE4","Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more than 2.25 million new cases of breast cancer in women in 2020. Although the modern treatment strategies, based on the complex care, which consists of surgery, radiotherapy, hormone therapy, and targeted chemotherapy directed at specific cancer molecules have substantially reduced the risk of death due to breast cancer, their wide adoption results in the wider prevalence of cardiotoxicity, defined as either symptomatic heart failure, or asymptomatic contractile dysfunction. The occurrence of cardiotoxicity induced by anti-cancer therapies is estimated at 5-15%, and its development is the primary cause of therapy termination, which significantly reduces the probability of the efficacy of treatment. Several attempts have been made to determine the efficacious preventive strategy, which could diminish the risk of cancer-therapy induced cardiotoxicity. The results of the prior studies indicated a trend towards lower risk of troponin elevation, or left ventricular contractile dysfunction with the introduction of drugs interfering with the renin-angiotensin-aldosterone (RAA) axis, which constitute the primary treatment modality in heart failure with reduced ejection fraction (HFrEF). Sacubitril\u002Fvalsartan, the novel therapeutic agent, has been demonstrated to significantly improve prognosis in patients with HFrEF. Prior retrospective, small, single-center studies have shown that treatment with sacubitril\u002Fvalsartan may reduce the risk of cancer-therapy induced cardiotoxicity, or reverse contractile dysfunction caused by anti-cancer therapy. However, no large randomized data confirmed these findings.\n\nTherefore, the Sacubitril\u002FValsartan in PriMAry preventIoN of the cardiotoxicity of systematic breaST canceR trEAtMent) study, has been designed to verify, whether the preventive use of sacubitril\u002Fvalsartan administered in the doses recommended in patients with HFrEF in breast cancer patients undergoing adjuvant chemotherapy with anthracyclines or anthracyclines and HER-2 monoclonal antibodies, will reduce the incidence of cardiotoxicity defined as impaired left ventricular systolic function on transthoracic echocardiography (TTE). In the trial, a total of 480 patients with histologically confirmed breast cancer, who are eligible for chemotherapy with anthracyclines or anthracyclines and HER-2 monoclonal antibodies, will undergo 1:1 randomization to either preventive treatment with sacubitril\u002Fvalsartan or placebo. The patients will be followed for 24 months, and will have repetitive efficacy and safety examinations, including echocardiography, MRI (optionally), electrocardiography including 24-h Holter monitoring, blood tests, functional capacity tests and quality of life assessment.",[125,126,127,128,129,130,131,132,31,133,134,27,69],"Breast Cancer","Neoplasm, Breast","Breast Diseases","Antihypertensive Agents","Sacubitril\u002FValsartan","Angiotensin II Type 1 Receptor Blockers","Angiotensin Receptor Antagonists","Molecular Mechanisms of Pharmacological Action","Cardiac Toxicity","Cancer, Therapy-Related",[136,129,137,138,28,125,69,72,101,139,140],"LCZ696","Magnetic Resonance Imaging","Echocardiography","Heart failure","Cardioprotection","RECRUITING","2025-03-11",{"date":102,"type":44},{"date":145,"type":44},"2024-04-17",{"date":147,"type":21},"2029-02",{"name":149,"class":51},"Silesian Centre for Heart Diseases",4,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":160,"conditions":161,"keywords":171,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":52},"100562965","cardiovascular-multimodality-imaging-study-100562965","NCT06610019","Cardiovascular Multimodality Imaging Study","Risk Stratification of Ischemic and Non-ischemic Cardiomyopathies in Racial and Ethnic Minority Groups in the Bronx - Cardiovascular Multimodality Imaging Study","Inclusion Criteria:\n\n* Any adult patient (18 years or older) referred for a cardiovascular magnetic resonance (CMR) imaging study in the Montefiore Health System\n\nExclusion Criteria:\n\n* Any patient who does not meet above criteria",{"count":159,"type":21},5000,"Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis. There is increased risk for cardiovascular disease and higher propensity for cardiovascular related mortality among Black and non-Hispanic White patients. Recently, advanced cardiac imaging has become a vital tool in diagnosis and risk stratification of cardiovascular disease. Very limited data is available on the prevalence and characteristics of different cardiovascular diseases in Hispanic and African American minority groups, therefore, studying different racial and ethnic minority groups in the Bronx population is an exceptionally valuable source to determine the prevalence of cardiomyopathies among minority groups along with study survival in this population. This study aims to determine the etiology of cardiovascular disease in a diverse patient population by utilizing various cardiovascular imaging modalities, with a focus on cardiac magnetic resonance (CMR) imaging and to develop risk stratification models by applying advanced cardiovascular imaging markers.",[162,163,164,165,166,167,168,169,170,31],"Non-ischemic Cardiomyopathy","Cardiomyopathies","Hypertrophic Cardiomyopathy","Right Ventricular Arrhythmogenic Cardiomyopathy","Cardiac Amyloidosis","Anderson Fabry Disease","Sarcoidosis","Cancer Therapy-related Cardiac Dysfunction","Ventricular Arrythmia",[172,173,174],"Cardiovascular Mortalities","Cardiomagnetic Resonance (CMR) Imaging","Prospective","2025-02-12",{"date":177,"type":44},"2025-02-14",{"date":179,"type":44},"2023-05-01",{"date":181,"type":21},"2031-12",{"name":183,"class":51},"Montefiore Medical Center",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":209,"leadSponsor":211,"locationsCount":52},"100495504","phase-2-nicotinamide-riboside-and-prevention-of-cancer-therapy-related-cardiac-dysfunction-in-breast-cancer-patients-100495504","NCT05732051","Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients","Effect of Nicotinamide Riboside on Myocardial and Skeletal Muscle Injury and Function in Patients With Metastatic Breast Cancer Receiving Anthracyclines","NARNIA","Inclusion Criteria:\n\n* Women with metastatic breast cancer (stage IV breast cancer) scheduled for anthracycline-containing chemotherapy\n* Eastern Cooperative Oncology Group performance status 0-2\n\nExclusion Criteria\n\n* Age \\\u003C18 years\n* Acute myocardial infarction within the last three months\n* Participation in another pharmaceutical clinical trial of an investigational medicinal product (IMP) less than 4 weeks prior to inclusion or use of other investigational drugs within 5 half-lives of enrollment, whichever is longer\n* Conditions that would affect the participants to comply with the study protocol as psychiatric or mental disorders, alcohol abuse or other substance abuse, suspected poor drug compliance, language barriers\n* Life expectancy \\\u003C 6 months\n* Known allergy to any of the components in the Nicotinamide Riboside (Niagen®) tablet\n* Contraindications or inability to undergo CMR examination",{"count":193,"type":21},60,[195],"PHASE2","Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure. In this study, the investigators want to evaluate whether nicotinamide riboside can prevent cancer-related cardiac dysfunction in metastatic breast cancer patients scheduled for anthracycline therapy. Further, the investigators will evaluate change in signs of skeletal muscle injury and functional capacity.",[125,198,27,69,31],"Metastatic Breast Cancer",[125,72,200,201,202,203,204,28,69,27],"Niagen","Nicotinamide riboside","Nicotinamide adenine dinucleotide","Reactive oxygen species","Cardiac Dysfunction","2023-03-16",{"date":207,"type":44},"2023-03-17",{"date":205,"type":44},{"date":210,"type":21},"2035-09-30",{"name":212,"class":51},"University Hospital, Akershus"]